Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Down 84.2% in December

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totaling 254 shares, a decline of 84.2% from the November 30th total of 1,606 shares. Based on an average trading volume of 4,132 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are sold short. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 4,132 shares, the short-interest ratio is currently 0.1 days.

Ascentage Pharma Group International Stock Performance

Shares of AAPG opened at $27.88 on Friday. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The stock has a 50-day moving average of $31.79 and a two-hundred day moving average of $36.69. Ascentage Pharma Group International has a one year low of $16.50 and a one year high of $48.45.

Analyst Upgrades and Downgrades

AAPG has been the topic of several research reports. Piper Sandler assumed coverage on Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective on the stock. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a report on Monday, November 24th. Oppenheimer assumed coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target on the stock. BTIG Research started coverage on shares of Ascentage Pharma Group International in a report on Monday, November 10th. They set a “buy” rating and a $50.00 target price on the stock. Finally, Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $48.50.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently bought and sold shares of AAPG. Tema Etfs LLC acquired a new position in Ascentage Pharma Group International during the second quarter worth $610,000. XY Capital Ltd boosted its position in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. UBS Group AG grew its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the third quarter worth about $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.